Phase 3 Clinical Trials With Primary Completion Dates in May 2019

This is a list of Phase 3 trials with primary completion dates in May 2019 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.

The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.

SymbolCompanyPrimary Completion DatePhaseNCT IDTitle
DCPHDeciphera Pharmaceuticals, Inc.2019-05-01Phase 3NCT03353753Phase 3 Study of DCC-2618 vs Placebo in Advanced GIST Patients Who Have Been Treated With Prior Anticancer Therapies
GRFSGrifols, S.A.2019-05-01Phase 3NCT02806986Efficacy, Pharmacokinetics, Safety, and Tolerability of IGSC 20% in Subjects With Primary Immunodeficiency
SNYSanofi2019-05-01Phase 3NCT03351478Efficacy and Safety of Sotagliflozin Versus Placebo and Empagliflozin in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking a DPP4 Inhibitor Alone or With Metformin
SNYSanofi2019-05-01Phase 3NCT03066830Efficacy and Safety of Sotagliflozin Versus Placebo in Patients With Type 2 Diabetes Mellitus on Background of Sulfonylurea Alone or With Metformin
SNYSanofi2019-05-01Phase 3NCT02926937Efficacy and Safety of Sotagliflozin Versus Placebo in Patients With Type 2 Diabetes Mellitus Not Currently Treated With Antidiabetic Therapy
SNYSanofi2019-05-01Phase 3NCT01957436A Phase III Study for Patients With Metastatic Hormone-naïve Prostate Cancer
SRPTSarepta Therapeutics, Inc.2019-05-01Phase 3NCT02255552Study of Eteplirsen in DMD Patients
VSTMVerastem, Inc.2019-05-01Phase 3NCT02049515A Phase 3 Extension Study of Duvelisib and Ofatumumab in Patients With CLL/SLL Previously Enrolled in Study IPI-145-07